Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children
- 31 July 1993
- journal article
- research article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 123 (1) , 81-84
- https://doi.org/10.1016/s0022-3476(05)81543-4
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2- to 4-month-old childrenThe Journal of Pediatrics, 1992
- Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDaVaccine, 1991
- Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.The Journal of Experimental Medicine, 1990
- Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old childrenThe Journal of Pediatrics, 1990